  | Sant'Angelo, D., DESCAMPS, G., LECOMTE, V., Stanicki, D., Penninckx, S., Dragan, T., Van Gestel, D., LAURENT, S., & JOURNE, F. (26 February 2025). Therapeutic Approaches with Iron Oxide Nanoparticles to Induce Ferroptosis and Overcome Radioresistance in Cancers. Pharmaceuticals (Basel, Switzerland), 18 (3), 325. doi:10.3390/ph18030325  Peer reviewed |
 | Genbauffe, A., Soumoy, L., Lefranc, F., & Journe, F. (September 2024). Reviewing Clinical Trials and Meta-Analyses to Assess the Efficacy and Safety of Huachansu in Cancer Treatment. Journal of Biomedical Research & Environmental Sciences, 5 (9), 1132-1139. doi:10.37871/jbres2001 Peer reviewed |
 | Scalia, A., Coquay, M., Kindt, N., DUEZ, P., Aro, R., JOURNE, F., Fabjanczyk, M., Trelcat, A., & CARLIER, S. (31 August 2024). In Vitro Modulation of Human Foam Cell Formation and Adhesion Molecules Expression by Ginger Extracts Points to Potential Cardiovascular Preventive Agents. International Journal of Molecular Sciences, 25 (17), 9487. doi:10.3390/ijms25179487 Peer Reviewed verified by ORBi |
 | Mhaidly, N., Barake, N., Trelcat, A., JOURNE, F., SAUSSEZ, S., & DESCAMPS, G. (01 August 2024). Bufalin Suppresses Head and Neck Cancer Development by Modulating Immune Responses and Targeting the β-Catenin Signaling Pathway. Cancers, 16 (15), 2739. doi:10.3390/cancers16152739 Peer Reviewed verified by ORBi |
 | Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G., Saussez, S., & Journe, F. (04 January 2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer Cell International, 24 (1), 8. doi:10.1186/s12935-023-03196-y Peer Reviewed verified by ORBi |
 | Kahvecioglu, Z. C., Vandecasteele, S., Bougard, M., Peeters, S., Daubry, A., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (24 November 2023). Innovative drug delivery system using EGFR-targeted engineered peptides in anaplastic thyroid cancer treatment [Poster presentation]. PhD Day SFMBBM 2023, Liège, Belgium. Peer reviewed |
 | Kahvecioglu, Z. C., Vandecasteele, S., Bougard, M., Rogien, C., Daubry, A., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (27 October 2023). Novel therapeutic approaches for EGFR-mediated drug delivery using engineered peptides in anaplastic thyroid cancer [Poster presentation]. Annual BACR Meeting 2023 Friday October 27th, CIRCADIAN CYCLE, CHRONOBIOLOGY AND CANCER, brussels, Belgium. Peer reviewed |
 | Mhaidly, N., STOCK, L., Descamps, G., Journe, F., Laurent, S., & Saussez, S. (27 October 2023). Development of a Macrophage-based Prognostic Scoring System and Evaluation of Bufalin as a Macrophage Phenotype Modulator in Head and Neck Cancer using 2D and 3D Models [Poster presentation]. BACR Annual meeting 2023 : Circadian cycle, chronobiology and cancer. Peer reviewed |
 | Bouland, C., Vanden Eynden, X., Lalmand, M., Buset, T., Yanni, A., Javadian, R., Rodriguez, A., Loeb, I., Lechien, J. R., Journe, F., SAUSSEZ, S., & Dequanter, D. (25 September 2023). Preventive and Therapeutic Effect of Metformin in Head and Neck Cancer: A Concise Review. Journal of Clinical Medicine, 12 (19), 6195. doi:10.3390/jcm12196195 Peer Reviewed verified by ORBi |
 | Mhaidly, N., Journe, F., Najem, A., Stock, L., Trelcat, A., Dequanter, D., SAUSSEZ, S., & DESCAMPS, G. (15 August 2023). Macrophage Profiling in Head and Neck Cancer to Improve Patient Prognosis and Assessment of Cancer Cell-Macrophage Interactions Using Three-Dimensional Coculture Models. International Journal of Molecular Sciences, 24 (16), 12813. doi:10.3390/ijms241612813 Peer Reviewed verified by ORBi |
 | Najem, A., Krayem, M., Sabbah, S., Pesetti, M., Journe, F., Awada, A., Désaubry, L., & Ghanem, G. E. (14 July 2023). Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies. Cells, 12 (14), 1855. doi:10.3390/cells12141855 Peer Reviewed verified by ORBi |
 | Kahvecioglu, Z. C., Samuel Vandecasteele, Marine Bougard, Charlotte Rogien, Journe, F., Laurent, S., Saussez, S., & Burtea, C. (02 July 2023). Development of a novel EGFR-targeted peptide for targeted delivery of drugs in anaplastic thyroid cancer [Poster presentation]. PBA 2023 33rd International Symposium on Pharmaceutical and Biomedical Analysis, ankara, Turkey. Peer reviewed |
 | Scalia, A., Doumani, L., Kindt, N., Journe, F., Trelcat, A., & Carlier, S. (22 June 2023). The Interplay between Atherosclerosis and Cancer: Breast Cancer Cells Increase the Expression of Endothelial Cell Adhesion Markers. Biology, 12 (7), 896. doi:10.3390/biology12070896 Peer Reviewed verified by ORBi |
 | Mhaidly, N., Descamps, G., Saussez, S., Journe, F., Laurent, S., & Stock, L. (20 June 2023). Development of a Macrophage-based Prognostic Scoring System and Evaluation of Bufalin as a Macrophage Phenotype Modulator in Head and Neck Cancer using 2D and 3D Models [Poster presentation]. FOCIS 2023 Annual Meeting. Peer reviewed |
 | Freis, B., Ramirez, M. D. L. A., Kiefer, C., Harlepp, S., Iacovita, C., HENOUMONT, C., Affolter-Zbaraszczuk, C., Meyer, F., Mertz, D., Boos, A., Tasso, M., Furgiuele, S., Journe, F., SAUSSEZ, S., Bégin-Colin, S., & LAURENT, S. (30 March 2023). Effect of the Size and Shape of Dendronized Iron Oxide Nanoparticles Bearing a Targeting Ligand on MRI, Magnetic Hyperthermia, and Photothermia Properties-From Suspension to In Vitro Studies. Pharmaceutics, 15 (4), 1104. doi:10.3390/pharmaceutics15041104 Peer Reviewed verified by ORBi |
 | Freis, B., Ramírez, M. D. L. Á., Furgiuele, S., Journe, F., Cheignon, C., Charbonnière, L. J., Henoumont, C., Kiefer, C., Mertz, D., Affolter-Zbaraszczuk, C., Meyer, F., Saussez, S., Laurent, S., Tasso, M., & Bégin-Colin, S. (25 March 2023). Bioconjugation studies of an EGF-R targeting ligand on dendronized iron oxide nanoparticles to target head and neck cancer cells. International Journal of Pharmaceutics, 635, 122654. doi:10.1016/j.ijpharm.2023.122654 Peer Reviewed verified by ORBi |
 | Kahvecioglu, Z. C., Toulehohoun, A., Feudjio Tagny, D., Rogien, C., Vandecasteele, S., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (02 February 2023). A study of combined targeted therapy and delivery, inducing an inhibition of PI3K/AKT/mTOR pathway in anaplastic thyroid cancer cells [Paper presentation]. 2023 Télévie Seminar, bruxelles, Belgium. |
 | Sabbah, M., Najem, A., Vanderkerkhove, C., Kert, F., Jourani, Y., Journe, F., Awada, A., Van Gestel, D., Ghanem, G. E., & Krayem, M. (2023). The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma. Frontiers in Medicine, 10, 1149918. doi:10.3389/fmed.2023.1149918 Peer Reviewed verified by ORBi |
 | Kehagias, P., Kindt, N., Krayem, M., Najem, A., Agostini, G., Acedo Reina, E., Bregni, G., Sclafani, F., Journe, F., Awada, A., Ghanem, G. E., & Hendlisz, A. (18 November 2022). Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance. Cells, 11 (22), 3663. doi:10.3390/cells11223663 Peer Reviewed verified by ORBi |
 | Descamps, G., Furgiuele, S., Mhaidly, N., Journe, F., & Saussez, S. (12 November 2022). Immune Cell Density Evaluation Improves the Prognostic Values of Staging and p16 in Oropharyngeal Cancer. Cancers, 14 (22), 5560. doi:10.3390/cancers14225560 Peer Reviewed verified by ORBi |
 | Scalia, A., Kindt, N., Trelcat, A., Nachtergael, A., Duez, P., Journe, F., & Carlier, S. (19 October 2022). Development of a Method for Producing oxLDL: Characterization of Their Effects on HPV-Positive Head and Neck Cancer Cells. International Journal of Molecular Sciences, 23 (20), 12552. doi:10.3390/ijms232012552 Peer Reviewed verified by ORBi |
 | Soumoy, L., Ghanem, G. E., Saussez, S., & Journe, F. (October 2022). Bufalin for an innovative therapeutic approach against cancer. Pharmacological Research, 184, 106442. doi:10.1016/j.phrs.2022.106442 Peer Reviewed verified by ORBi |
Soumoy, L., Wells, M., Najem, A., Krayem, M., Ghanem, G., Hambye, S., Saussez, S., Blankert, B., & Journe, F. (12 September 2022). Uncovering the antiproliferative potential of toad venoms on metastatic melanoma [Poster presentation]. 12th International Symposium of Drug Analysis 32nd International Symposium on Pharmaceutical and Biomedical Analysis, Mons, Belgium. Peer reviewed |
| Kahvecioglu, Z. C., Toulehohoun, A., Feudjio Tagny, D., Rogien, C., Vandecasteele, S., Rogien, C., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (11 September 2022). Novel therapeutic strategy targeting the EGFR and inhibiting PI3K/AKT/mTOR pathway in anaplastic thyroid carcinoma [Poster presentation]. 12th International Symposium on Drug Analysis & 32nd International Symposium on Pharmaceutical and Biomedical Analysis, Mons, Belgium. Peer reviewed |
Mhalaidly, N., Descamps, G., Journe, F., Laurent, S., & Saussez, S. (09 September 2022). Macrophage Plasticity and Function in the Head and Neck Tumor Microenvironment in 3D multicellular Spheroid model [Poster presentation]. Interuniversity PhD Student Day’ organisé par l’EDT-Biologie Cellulaire et Moléculaire &Biochimie. |
 | Yanni, A., Buset, T., Bouland, C., Loeb, I., Lechien, J. R., Rodriguez, A., Journe, F., Saussez, S., & Dequanter, D. (August 2022). Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck cancer with lung metastasis: a retrospective study. European Archives of Oto-Rhino-Laryngology, 279 (8), 4103 - 4111. doi:10.1007/s00405-022-07274-1 Peer Reviewed verified by ORBi |
 | {"lastName":"Marin", F. J. A. L. O. C. A. E. O. L. I. J. B. U. L. D. B. U. B. B. I. S. O., Journe, F., Ghanem, G. E., {"lastName":"Awada", F. A. A. L. O. C. A. E. O. L. I. J. B. U. L. D. B. U. B. B. D. O. M. O. I. J. B. U. L. D. B. U. B. B. I. S. O., & Kindt, N. (28 June 2022). Cytokine Landscape in Central Nervous System Metastases. Biomedicines, 10 (7), 1537. doi:10.3390/biomedicines10071537 Peer Reviewed verified by ORBi |
 | Furgiuele, S., {"lastName":"Descamps", F. G. A. U. D. M.-U. U. E. F. D. M. E. D. P. U. E. S. D. U. A. H. E. O. E. I. S. O.-X., {"lastName":"Lechien", F. J. R. A. D. O. O. A. H. A. N. S. C. S.-P. B. B. I. S. O., {"lastName":"Dequanter", F. D. A. D. O. O. A. H. A. N. S. C. S.-P. B. B. I. S. O., Journe, F., & {"lastName":"Saussez", F. S. A. U. D. M.-U. U. E. F. D. M. E. D. P. U. E. S. D. U. A. H. E. O. E. D. O. O. A. H. A. N. S. C. S.-P. B. B. I. S. O. (28 June 2022). Immunoscore Combining CD8, FoxP3, and CD68-Positive Cells Density and Distribution Predicts the Prognosis of Head and Neck Cancer Patients. Cells, 11 (13), 2050. doi:10.3390/cells11132050 Peer Reviewed verified by ORBi |
Furgiuele, S., Descamps, G., Freis, B., Begin, S., Journe, F., Laurent, S., & Saussez, S. (21 June 2022). Improving treatment response in head and neck cancers by a dual effect: targeting tumour cells and tumour microenvironment [Poster presentation]. EACR 2022. Peer reviewed |
 | Furgiuele, S., {"lastName":"Descamps", F. G. A. U. D. M.-U. U. E. F. D. M. E. D. P. U. E. S. D. U. A. H. E. O. E. I. S. O.-X., Cascarano, L., Boucq, A., Dubois, C., Journe, F., & {"lastName":"Saussez", F. S. A. U. D. M.-U. U. E. F. D. M. E. D. P. U. E. S. D. U. A. H. E. O. E. D. O. O. A. H. A. N. S. C. S.-P. B. B. I. S. O. (07 June 2022). Dealing with Macrophage Plasticity to Address Therapeutic Challenges in Head and Neck Cancers. International Journal of Molecular Sciences, 23 (12), 6385. doi:10.3390/ijms23126385 Peer Reviewed verified by ORBi |
Kahvecioglu, Z. C., Toulehohoun, A., Feudjio Tagny, D., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (08 April 2022). PI3K/AKT/mTOR pathway inhibition and targeted drug delivery combined in a novel therapeutic strategy addressed to anaplastic thyroid carcinoma [Poster presentation]. Séminaire Télévie. Peer reviewed |
 | Najem, A., Soumoy, L., Sabbah, M., Krayem, M., {"lastName":"Awada", F. A. A. L. O. C. A. E. O. L. I. J. B. U. L. D. B. B. B. D. O. M. O. I. J. B. U. L. D. B. B. B. I. S. O., Journe, F., & Ghanem, G. E. (29 March 2022). Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma. Cells, 11 (7), 1157. doi:10.3390/cells11071157 Peer Reviewed verified by ORBi |
 | Freis, B., Furgiuele, S., Kiefer, C., Henoumont, C., Affolter-Zbaraszczuk, C., Mertz, D., Harlepp, S., Meyer, F., Journe, F., Saussez, S., Laurent, S., & Bégin-Colin, S. (08 December 2021). Targeting strategy for a high selective accumulation and therapeutic efficiency of dendronized nanoparticles in head and neck cancer cells [Poster presentation]. Congres SFNano, Angers, Unknown/unspecified. |
Soumoy, L., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (07 December 2021). Bufalin to fight persister cells and breakdown resistance to targeted therapies in metastatic melanoma [Poster presentation]. EACR-AstraZeneca Virtual Conference 'Drug Tolerant Persister Cells', . |
Soumoy, L., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (03 December 2021). Targeting tumor cell metabolic plasticity to breakdown resistance to targeted therapies in metastatic melanoma [Paper presentation]. ESPCR-2021, Virtual, Unknown/unspecified. |
Najem, A., Wouters, J., Krayem, M., Rambow, F., Sabbah, M., Sales, F., Awada, A., Aerts, S., Journe, F., Marine, J., & Ghanem, G. (01 November 2021). Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value. Frontiers in Oncology, 11, 780654. Peer reviewed |
Lechien, J., Journe, F., Saussez, S., & en collaboration avec 9 personnes. (2021). Prognostic Significance of a Scoring System Combining p16, Smoking, and Drinking Status in a Series of 131 Patients with Oropharyngeal Cancers. International Journal of Otolaryngology. Peer Reviewed verified by ORBi |
Freis, B., Kiefer, C., Mertz, D., Henoumont, C., Affolter-Zbaraszczuk, C., Harlepp, S., Meyer, F., Furgiuele, S., Journe, F., Saussez, S., Laurent, S., & Bégin-Colin, S. (27 August 2021). Mastering size and shape of iron oxide nanoparticles for the development of theranostic nano-objects for head and neck cancers [Poster presentation]. 16th European Molecular Imaging Meeting, ESMI, Lokhalle Göttingen, Allemagne, . |
Lechien, J., Journe, F., Saussez, S., & en collaboration avec 12 personnes. (2021). Epidemiological, otolaryngological, olfactory and gustatory outcomes according to the severity of COVID-19: a study of 2579 patients. European Archives of Oto-Rhino-Laryngology. Peer Reviewed verified by ORBi |
Lechien, J., Saussez, S., Journe, F., & en collaboration avec 12 personnes. (2021). Correction to: Epidemiological, otolaryngological, olfactory and gustatory outcomes according to the severity of COVID-19: a study of 2579 patients. European Archives of Oto-Rhino-Laryngology. Peer Reviewed verified by ORBi |
Soumoy, L., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (10 June 2021). Evaluating metabolic reprogramming in metastatic melanoma with resistance to targeted therapies to assess new targets for treatment [Poster presentation]. EACR-2022, Virtual, Unknown/unspecified. |
Freis, B., Perton, F., Kiefer, C., Mertz, D., Henoumont, C., Affolter-Zbaraszczuk, C., Harlepp, S., Meyer, F., Furgiuele, S., Journe, F., Saussez, S., Laurent, S., & Bégin-Colin, S. (04 June 2021). Mastering size and shape for the design of innovative theranostic iron oxide based nanoparticles ensuring multimodal therapy [Paper presentation]. EMRS Sprint Meeting, Congrès Virtuel, Belgium. |
 | Kahvecioglu, Z. C., Gheysen, L., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (21 May 2021). Toward the development of peptide inhibitors targeted to PI3K/AKT signalling pathway for the therapy of anaplastic thyroid carcinoma [Poster presentation]. 27th Porto Cancer meeting Stemness & Metastasis: Advances in Research and Clinical Translation, Porto, Portugal. |
Gheysen, L., Soumoy, L., Trelcat, A., Verset, L., Journe, F., & Saussez, S. (2021). New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer. Cells. Peer Reviewed verified by ORBi |
 | Kindt, N., Journe, F., Carlier, S., Trelcat, A., Scalia, A., & Saussez, S. (05 May 2021). Effect of Oxidized Low-Density Lipoprotein on Head and Neck Squamous Cell Carcinomas. Biomedicines, 9 ((5)), 513. Peer Reviewed verified by ORBi |
 | Absil, L., Rigaux, E., Tafforeau, L., Body, J.-J., Nonclercq, D., & Journe, F. (01 April 2021). Involvement of FXR in the OPG/RANKL pathway of breast and prostate cancer cells. Bone Reports, 14, 101036. doi:10.1016/j.bonr.2021.101036 Peer Reviewed verified by ORBi |
Freis, B., Cotin, G., Perton, F., Kiefer, C., Ayela, C., Felder-Flesch, D., Mertz, D., Henoumont, C., Zbaraszczuk-Affolter, C., Harlepp, S., Meyer, F., Furgiuele, S., Journe, F., Saussez, S., Laurent, S., & Begin-Colin, S. (30 March 2021). Tuning size and shape of iron oxide nanoparticles ensuring multimodal therapy for head and neck cancers [Poster presentation]. Mardi des Chercheurs, Virtual Meeting, Unknown/unspecified. |
Lechien, J., Journe, F., Saussez, S., & en collaboration avec 12 personnes. (2021). Psychophysical Evaluation of the Olfactory Function: European Multicenter Study on 774 COVID-19 Patients. Pathogens. Peer Reviewed verified by ORBi |
 | de Bakker, T., Journe, F., Saussez, S., Dragan, T., Ghanem, G., Krayem, M., Van Gestel, D., & Descamps, G. (2021). Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments. Frontiers in Oncology, 11, 799993. doi:10.3389/fonc.2021.799993 Peer Reviewed verified by ORBi |
Lechien, J., Journe, F., Hans, S., Chiesa-Estomba, C., Mustin, V., Beckers, E. H. A., Vaira, L., De Riu, G., Hopkins, C., & Saussez, S. (2020). Severity of Anosmia as an Early Symptom of COVID-19 Infection May Predict Lasting Loss of Smell. Frontiers in Medicine. Peer Reviewed verified by ORBi |
Lardinois, , Dequanter, D., Lechien, J., Bouland, C., Javadian, R., Rodriguez, A., Loeb, I., Journe, F., & Saussez, S. (2020). Survival and treatment outcome of head and neck cancer patients with pulmonary oligometastases. Clinical Otolaryngology. Peer Reviewed verified by ORBi |
Descamps, G., Verset, L., Trelcat, A., Hopkins, C., Lechien, J., Journe, F., & Saussez, S. (2020). ACE2 Protein Landscape in the Head and Neck Region: The Conundrum of SARS-CoV-2 Infection. Biology. Peer Reviewed verified by ORBi |
 | Soumoy, L., Wells, M., Ahmad, N., Krayem, M., Ghanem, G., Hambye, S., Saussez, S., Blankert, B., & Journe, F. (2020). 'Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms'. Biology, (9), 218-234. Peer Reviewed verified by ORBi |
Lechien, J., Ducarme, M., Place, S., Chiesa-Estomba, C. M., Khalife, M., De Riu, G., Vaira, L., De Terwangne, C., Machayekhi, S., Marchant, A., Journe, F., & Saussez, S. (2020). Objective Olfactory Findings in Hospitalized Severe COVID-19 Patients. Pathogens. Peer Reviewed verified by ORBi |
 | Absil, L., Journe, F., Larsimont, D., Body, J.-J., Tafforeau, L., & Nonclercq, D. (10 July 2020). Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells. BMC Cancer, 20, 640. doi:10.1186/s12885-020-07106-7 Peer Reviewed verified by ORBi |
 | Lechien, J., Chiesa-Estomba, C. M., De Siati, D. R., Horoi, M., Le Bon, S., Rodriguez, A., Dequanter, D., Blecic, S., El Afia, F., Distinguin, L., Chekkoury-Idrissi, Y., Hans, S., Lopez-Delgado, I., Calvo-Henriquez, C., Lavigne, P., Falanga, C., Barillari, M. R., Cammaroto, G., Khalife, M., ... Saussez, S. (04 June 2020). Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. European Archives of Oto-Rhino-Laryngology, Apr 6, 1-11. doi:10.1007/s00405-020-05965-1 Peer Reviewed verified by ORBi |
Lechien, J., Chiesa-Estomba, C., Cabaraux, P., Mat, Q., Huet, K., Harmegnies, B., Horoi, M., Bon, S., Rodriguez, A., Dequanter, D., Hans, S., Crevier-Buchman, L., Hochet, B., Distinguin, L., Chekkoury-Idrissi, Y., Circiu, M., El Afia, F., Barillari, M., Cammaroto, G., ... Saussez, S. (2020). Features of Mild-to-Moderate COVID-19 Patients With Dysphonia. Journal of Voice. doi:10.1016/j.jvoice.2020.05.012 Peer Reviewed verified by ORBi |
 | Soumoy, L., Schepkens, C., Krayem, M., Ahmad, N., Tagliatti, V., Ghanem, E. G., Saussez, S., Colet, J.-M., & Journe, F. (22 May 2020). Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis. Cancers, 12 (5), 12-23. doi:10.3390/cancers12051323 Peer Reviewed verified by ORBi |
Lechien, J., Cabaraux, P., Chiesa-Estomba, C., Khalife, M., Hans, S., Calvo-Henriquez, C., Martiny, D., Journe, F., Sowerby, L., & Saussez, S. (2020). Objective olfactory evaluation of self-reported loss of smell in a case series of 86 COVID-19 patients. Archives of Otolaryngology - Head and Neck Surgery. Peer Reviewed verified by ORBi |
Lechien, J., Descamps, G., Seminerio, I., Furgiuele, S., Dequanter, D., Mouawad, F., Badoual, C., Journe, F., & Saussez, S. (2020). HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas. Cancers. Peer Reviewed verified by ORBi |
  | Gheysen, L., Saussez, S., & Journe, F. (2020). Combinatorial therapies in Thyroid cancer: An Overview of Preclinical and Clinical Progresses. Cells. Peer Reviewed verified by ORBi |
 | Kindt, N., Journe, F., Saussez, S., & Carlier, S. (13 February 2020). Involvement of oxLDL in the biology of head and neck cancer cell lines [Paper presentation]. 39th Annual Belgian Society of Cardiology Meeting, Bruxelles, Unknown/unspecified. |
Gheysen, L., Saussez, S., & Journe, F. (07 February 2020). Combination of targeted therapies implicating p53 reactivator, PRIMA -1Met and SRC inhibitor, dasatinib in anaplastic thyroid cancer [Poster presentation]. BACR Annual meeting, Jette, Belgium. |
Soumoy, L., Trelcat, A., Schepkens, C., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (31 January 2020). Metabolic switch in melanoma cells with acquired resistance to targeted therapies [Poster presentation]. BACR Annual meeting, Jette, Belgium. |
Soumoy, L., Trelcat, A., Schepkens, C., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (31 January 2020). Metabolic switch in melanoma cells with acquired resistance to targeted therapies [Poster presentation]. 14th meeting of the FRS-FNRS Contact group on Oxidative Proceses and Antioxidants, UMONS, Belgium. |
Gheysen, L., Saussez, S., & Journe, F. (29 January 2020). Combination of targeted therapies including p53 reactivator, PRIMA 1Met and SRC inhibitor, dasatinib in thyroid cancer [Poster presentation]. Séminaire des chercheurs Télévie 2020, Campus Woluwe, UCL, Bruxelles, Belgium. |
Wells, M., Soumoy, L., Journe, F., Saussez, S., Hambye, S., & Blankert, B. (04 December 2019). Bio-guided fractionation for the isolation of antiplasmodial and cytotoxic compounds from the venom of Bufo toads [Paper presentation]. 26ème RT-SFET, Paris, France. Peer reviewed |
Soumoy, L., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (25 October 2019). Mechanisms of resistance in melanoma cells and the role of Mnk proteins in these processes [Poster presentation]. 4th symposium of the ULB-cancer research center, Brussels , Belgium. |
Gheysen, L., Saussez, S., & Journe, F. (25 October 2019). Combination of targeted therapies implicating p53 reactivator, PRIMA -1Met and SRC inhibitor, dasatinib in anaplastic thyroid cancer [Poster presentation]. 4th annual symposium of the ULB-cancer research center, Brussels, Belgium. |
Lechien, J., Seminerio, I., Descamps, G., Mat, Q., Mouawad, F., Hans, S., Julieron, M., Dequanter, D., Vanderhaegen, T., Journe, F., & Saussez, S. (2019). Impact of HPV Infection on the Immune System in Oropharyngeal and Non-Oropharyngeal Squamous Cell Carcinoma: A Systematic Review. Cells. Peer Reviewed verified by ORBi |
Furgiuele, S., Descamps, G., Tafforeau, L., Tagliatti, V., Journe, F., & Saussez, S. (06 September 2019). Development and application of the CRISPR-Cas9 technique in human cell lines of head and neck cancers infected with human papillomavirus [Poster presentation]. Ecole Doctorale en Cancérologie, UCL, Belgium. Peer reviewed |
Soumoy, L., Najem, A., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (06 September 2019). Mechanisms of resistance in melanoma cells and the role of Mnk proteins in these processes [Paper presentation]. EDT-Cancerology Annual Meeting 2019, UCLouvain, Belgium. |
 | Descamps, G., Saussez, S., & Journe, F. (2019). Current and future markers for the diagnosis of thyroid cancer. CLINICAL ONCOLOGY AND RESEARCH. Peer reviewed |
Bobin, F., Journe, F., & Lechien, J. (2019). Saliva pepsin level of laryngopharyngeal reflux patients is not correlated with reflux episodes. Laryngoscope. Peer Reviewed verified by ORBi |
Krayem, M., Sabbah, M., Najem, A., Wouters, A., Lardon, F., Simon, S., Sales, F., Journe, F., Awada, A., Ghanem, G., & Van Gestel, D. (01 August 2019). The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers, 11 (8), 1093. Peer reviewed |
Lechien, J., Saussez, S., Schindler, A., Karkos, P., Hamdan, A., Harmegnies, B., De Marrez, L., Finck, C., Journe, F., Paesmans, M., & Vaezi, M. (01 May 2019). Clinical outcomes of laryngopharyngeal reflux treatment: A systematic review and meta-analysis. Laryngoscope, 129 (5), 1174-1187. Peer Reviewed verified by ORBi |
 | Soumoy, L., Kindt, N., Ghanem, G., Saussez, S., & Journe, F. (2019). Role of Macrophage Migration Inhibitory Factor (MIF) in melanoma. Cancers. Peer Reviewed verified by ORBi |
Gheysen, L., Saussez, S., & Journe, F. (14 March 2019). New combination of targeted therapies for thyroid cancer treatment [Poster presentation]. 7th ICHNO Head and Neck oncology, Barcelona, Spain. |
Absil, L., Rigaux, E., Journe, F., & Nonclercq, D. (05 March 2019). The role of FXR in the osteomimicry of PC-3 prostate cancer cells [Poster presentation]. Mardi des Chercheurs, Mons, Belgium. |
Soumoy, L., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (05 March 2019). New combinations of targeted therapies in melanoma [Poster presentation]. Mardi des Chercheurs, Mons, Belgium. |
Furgiuele, S., Descamps, G., Stanicki, D., Journe, F., Laurent, S., & Saussez, S. (05 March 2019). Protontherapy for Head and Neck Cancers [Poster presentation]. Mardi des Chercheurs 2019 (MdC2019), Mons, Belgium. |
Journe, F. (01 March 2019). Brevican is a proteoglycan related to MITF activity with a prognostic value in melanoma [Poster presentation]. BACR Annual meeting, Antwerpen, Belgium. |
 | Seminerio, I., Descamps, G., Dupont, S., de Marrez, L., Laigle, J.-A., Lechien, J., Kindt, N., Journe, F., & Saussez, S. (15 February 2019). Infiltration of FoxP3+ Regulatory T Cells is a Strong and Independent Prognostic Factor in Head and Neck Squamous Cell Carcinoma. Cancers, 11 (227). doi:10.3390/cancers11020227 Peer Reviewed verified by ORBi |
 | Kindt, N., Descamps, G., Lechien, J., Remmelink, M., Colet, J.-M., Wattiez, R., Berchem, G., Journe, F., & Saussez, S. (02 February 2019). Involvement of HPV Infection in the Release of Macrophage Migration Inhibitory Factor in Head and Neck Squamous Cell Carcinoma. Journal of Clinical Medicine, 1#0 (8). Peer Reviewed verified by ORBi |
 | Soumoy, L., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (01 February 2019). New combinations of targeted therapies in melanoma [Poster presentation]. BACR Annual meeting, Antwerpen, Belgium. |
Gheysen, L., Saussez, S., & Journe, F. (01 February 2019). Combination of p53 reactivator and SRC inhibitor in thyroid cancer treatment [Poster presentation]. BACR Annual meeting, Antwerpen, Belgium. |
Absil, L., Journe, F., & Nonclercq, D. (28 January 2019). The role of FXR in the osteomimetism in MDA-MB-231 Breast Cancer Cells [Paper presentation]. Televie Cancer Seminar 2019, Gembloux, Belgium. |
Gheysen, L., Saussez, S., & Journe, F. (28 January 2019). Combination of p53 reactivator and SRC inhibitor in thyroid cancer treatment [Poster presentation]. Séminaire des chercheurs Télévie 2019, Gembloux, Belgium. |
 | Kindt, N., Descamps, G., Lechien, J., Remmelink, M., Colet, J.-M., Wattiez, R., Berchem, G., Journe, F., & Saussez, S. (2019). Involvement of HPV Infection in the release of macrophage migration inhibitory factor in head and neck squamous cell carcinoma. In Journal of Clinical Medecine. mdpi. |
Lechien, J., Saussez, S., Schindler, A., Karkos, P., Hamdan, A. L., Harmegnies, B., De Marrez, L., Finck, C., Journe, F., Paesmans, M., & Vaezi, M. (2018). Clinical outcomes of laryngopharyngeal reflux treatment: A systematic review and meta-analysis. Laryngoscope. Peer Reviewed verified by ORBi |
Absil, L., Journe, F., & Nonclercq, D. (13 September 2018). Role of the farnesoid X receptor in the osteotropism of breast cancer cells [Paper presentation]. GIGA - cancer days 2018, Liège, Belgium. |
  | Krayem, M., Najem, A., Journe, F., Morandini, R., Sales, F., Awada, A., & Ghanem, G. (07 August 2018). [RETRACTED] Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma. Oncotarget, 9 (61), 31888-31903. Peer Reviewed verified by ORBi |
Absil, L., Journe, F., & Nonclercq, D. (08 June 2018). The role of FXR in the osteomimetism in MCF-7 Breast Cancer Cells [Poster presentation]. Belgian Society for Cell and Development Biology, Liège, Belgium. |
Gheysen, L., Saussez, S., & Journe, F. (15 May 2018). Nouvelle combinaison de traitements ciblés dans le cadre du cancer thyroïdien [Paper presentation]. 'La parole aux jeunes chercheurs', Université de Mons, Belgium. |
Absil, L., Journe, F., & Nonclercq, D. (27 March 2018). The role of FXR in the osteomimetism in MCF-7 Breast Cancer Cells [Poster presentation]. Mardi des Chercheurs (MdC2018), Valenciennes, France. |
Gheysen, L., Saussez, S., & Journe, F. (27 March 2018). New targeted therapy combination for thyroid cancer [Poster presentation]. Mardi des chercheurs, Université de Valenciennes, France. |
Seminerio, I., Journe, F., & Saussez, S. (27 March 2018). High infiltration of CD68+ macrophages is associated with poor prognoses of head and neck squamous cell carcinoma patients and is influenced by human papillomavirus [Poster presentation]. Mardi des Chercheurs (MdC2018), Valenciennes, France. |
Absil, L., Journe, F., & Nonclercq, D. (07 March 2018). Implication du FXR dans l'ostéomimétisme des cellules cancéreuses mammaires MCF-7 [Paper presentation]. Journée doctorale transfrontalière, Reims, France. |
Gheysen, L., Saussez, S., & Journe, F. (01 February 2018). New targeted therapy combination for thyroid cancer [Paper presentation]. Séminaire des chercheurs Télévie 2018, Bruxelles , Belgium. |
Absil, L., Journe, F., & Nonclercq, D. (01 February 2018). The role of FXR in the osteomimetism in MCF-7 Breast Cancer Cells [Poster presentation]. télévie Cancer Seminar, Bruxelles (Erasme), Belgium. |
 | Seminerio, I., Kindt, N., Descamps, G., Bellier, J., Lechien, J., Mat, Q., Pottier, C., Journe, F., & Saussez, S. (24 January 2018). High infiltration of CD68+ macrophages is associated with poor prognoses of head and neck squamous cell carcinoma patients and is influenced by human papillomavirus. Oncotarget, 9 (13), 11046-11059. doi:10.18632/oncotarget.24306 Peer Reviewed verified by ORBi |
Kindt, N., Journe, F., Ghanem, G., & Saussez, S. (18 December 2017). Galectins and Carcinogenesis: Their Role in Head and Neck Carcinomas and Thyroid Carcinomas. International Journal of Molecular Sciences, 18 (12). Peer Reviewed verified by ORBi |
Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M. (16 December 2017). PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies. Cancers, 9 (12), 1-17. Peer Reviewed verified by ORBi |
Najem, A., Krayem, M., Perdrix, A., Kerger, J., Awada, A., Journe, F., & Ghanem, G. (01 December 2017). New Drug Combination Strategies in Melanoma: Current Status and Future Directions. Anticancer Research, 37 (11), 5941-5953. Peer Reviewed verified by ORBi |
Absil, L., Journe, F., & Nonclercq, D. (07 November 2017). Osteotropism induced by CDCA is interfered by lithocholic acid in breast cancer [Paper presentation]. European Gynecological Oncology Congress, Vienna, Austria. |
Gilot, D., Migault, M., Bachelot, L., Journe, F., Rogiers, A., Donnou-Fournet, E., Mogha, A., Mouchet, N., Pinel-Marie, M., Mari, B., Montier, T., Corre, S., Gautron, A., Rambow, F., El Hajj, P., Ben Jouira, R., Tartare-Deckert, S., Marine, J., Felden, B., ... Galibert, M.-D. (01 November 2017). A non-coding function of TYRP1 mRNA promotes melanoma growth. Nature Cell Biology, 19 (11), 1348-1357. Peer Reviewed verified by ORBi |
Zhan, Y., Guo, J., Yang, W., Goncalves, C., Rzymski, T., Dreas, A., Zylkjewicz, E., Mikulski, M., Brzózka, K., Golas, A., Kong, Y., Ma, M., Huang, F., Huor, B., Guo, Q., Da Silva, S., Torres, J., Cai, Y., Topisirovic, I., ... Del Rincon, S. (01 November 2017). MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. Journal of Clinical Investigation, 127 (11), 4179-4192. Peer Reviewed verified by ORBi |
Arcolia, V., Journe, F., Renaud, F., Leteurte, E., Gabius, H., Remmelink, M., & Saussez, S. (01 October 2017). Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer. Oncology Letters, 14 (4), 4183-4189. Peer Reviewed verified by ORBi |
Lechien, J., Nassri, A., Kindt, N., Brown, D., Journe, F., & Saussez, S. (2017). Role of macrophage migration inhibitory factor in head and neck cancer and novel therapeutic targets: A systematic review. Head and Neck. Peer Reviewed verified by ORBi |
Kindt, N., Descamps, G., Seminerio, I., Bellier, J., Lechien, J., Mat, Q., Pottier, C., Delvenne, P., Journe, F., & Saussez, S. (22 September 2017). High stromal Foxp3-positive T cell number combined to tumor stage improved prognosis in head and neck squamous cell carcinoma [Poster presentation]. Second symposium of the ULB-cancer research center, Bruxelles, Belgium. |
Gheysen, L., Saussez, S., & Journe, F. (22 September 2017). New targeted therapy combination for thyroid cancer [Poster presentation]. Second symposium of the ULB cancer research centre (U-CRC), ULB, Bruxelles, Belgium. |
Najem, A., Krayem, M., Sales, F., Hussein, N., Badran, B., Robert, C., Awada, A., Journe, F., & Ghanem, G. (01 September 2017). P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. European Journal of Cancer, 83, 154-165. Peer Reviewed verified by ORBi |
 | Arcolia, V., Journe, F., Wattiez, R., Leteurte, E., Renaud, F., Gabius, H., Remmelink, M., Decaestecker, C., Rodriguez, A., Boutry, S., Laurent, S., & Saussez, S. (01 September 2017). Galectin-1 is a diagnostic marker involved in thyroid cancer progression. International Journal of Oncology, 51 (3), 760-770. Peer Reviewed verified by ORBi |
Absil, L., Journe, F., & Nonclercq, D. (18 May 2017). Osteotropism in MCF-7 Breast Cancer Cells [Poster presentation]. BIT's 10th Annual World Cancer Congress 2017, Barcelona, Spain. |
Seminerio, I., Kindt, N., Descamps, G., Bellier, J., Lechien, J., Mat, Q., Pottier, C., Delvenne, P., Journe, F., & Saussez, S. (18 May 2017). Stromal FoxP3-positive T Cell Number Combined to Tumor Stage Improves Prognosis in Head and Neck Squamous Cell Carcinoma [Poster presentation]. BIT's 10th Annual World Cancer Congress 2017, Barcelona, Spain. |
Kindt, N., Descamps, G., Seminerio, I., Bellier, J., Lechien, J., Mat, Q., Pottier, C., Delvenne, P., Journe, F., & Saussez, S. (08 March 2017). High stromal Foxp3-positive T cell number combined to tumor stage improved prognosis in head and neck squamous cell carcinoma. Oral Oncology, 67, 183-191. Peer Reviewed verified by ORBi |
Absil, L., Journe, F., Saussez, S., & Nonclercq, D. (07 March 2017). Chenodeoxycholic acid (CDCA) promotes osteomimetism in MDA-MB-231 cells [Poster presentation]. Huitième édition montoise du MdC : le Mardi des Chercheurs 2017, UMons, Belgium. |
Najar, M., Fayyad-Kazan, H., Faour, W., Badran, B., Journe, F., & Lagneaux, L. (01 February 2017). Breast cancer cells and bone marrow mesenchymal stromal cells: a regulated modulation of the breast tumor in the context of immune response. Inflammation Research, 66 (2), 129-139. Peer Reviewed verified by ORBi |
Absil, L., Journe, F., Saussez, S., & Nonclercq, D. (08 December 2016). Bile acids promote osteomimetism in MDA-MB-231 cells [Poster presentation]. télévie's Researchers Seminar, UCL Bruxelles, Belgium. |
Kindt, N., Descamps, G., Seminerio, I., Bellier, J., Lechien, J., Pottier, C., Larsimont, D., Journe, F., Delvenne, P., & Saussez, S. (01 November 2016). Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas. Oral Oncology, 62 (2016), 1-10. Peer Reviewed verified by ORBi |
Absil, L., Journe, F., laurent, G., Larsimont, D., Saussez, S., Body, J.-J., & Nonclercq, D. (08 September 2016). Bile acids and estrogens promote the cell proliferation and osteomimetism in MCF-7 cells [Poster presentation]. RBSM Golden Jubilee Meeting of the Royal Belgium Society for Microscopy, Bruxelles, Belgium. |
Kindt, N., Journe, F., Laurent, G., & Saussez, S. (02 August 2016). Involvement of macrohage migration inhibitory factor in cancer and novel therapeutic targets (Review). Oncology Letters, 12, 2247-2253. Peer Reviewed verified by ORBi |
Arcolia, V., Journe, F., Wattier, A., Leteurtre, E., Gabius, H.-J., Remmelink, M., Decaestecker, C., Rodriguez, A., Boutry, S., Laurent, S., & Saussez, S. (01 July 2016). Galectin-1 as a diagnostic marker involved in thyroid cancer progression [Poster presentation]. Symposium of ULB-Cancer Research Centre (U-CRC), Erasme, Belgium. |
Descamps, G., Karaca, Y., Lechien, J., Kindt, N., Decaestecker, C., Remmelink, M., Larsimont, D., Andry, G., Hassid, S., Rodriguez, A., Khalife, M., Journe, F., & Saussez, S. (01 July 2016). Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients. Journal of Cancer Research and Clinical Oncology, 152 (10), 2185-2196. Peer Reviewed verified by ORBi |
Absil, L., Journe, F., laurent, G., Larsimont, D., Saussez, S., Body, J.-J., & Nonclercq, D. (01 July 2016). Farnesoid X receptor expression predicts bone metastases from breast cancer [Poster presentation]. Opening Symposium of the ULB- cancer research centre, Brussels, Belgium. |
Absil, L., Journe, F., & Nonclercq, D. (27 May 2016). FXR is involved in the control of cell proliferation in breast cancer cells [Poster presentation]. Stem Cells as Disease Model and for Gene Therapy, Brussels, Belgium. |
Brouwers, B., Hatse, S., Dal Lago, L., Neven, P., Vuylsteke, P., Dalmasso, B., Debrock, G., Van Den Bulck, H., Smeets, A., Bechter, O., Bailur, J., Kenis, C., Laenen, A., Schoffski, P., Pawelec, G., Journe, F., Ghanem, G., & Wildiers, H. (2016). The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget. Peer Reviewed verified by ORBi |
Absil, L., Journe, F., & Nonclercq, D. (18 May 2016). Implication du FXR dans la prolifération cellulaire des cellules de carcinomes mammaires [Poster presentation]. Matinée des chercheurs, Valenciennes, Université de Valenciennes et du Hainaut Cambrésis, France. |
Krayem, M., Journe, F., Weidig, M., Morandini, R., Najem, A., Salès, F., van Kempen, L., Sibille, C., Awada, A., Marine, J., & Ghanem, G. (01 March 2016). p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. European Journal of Cancer, 55, 98-110. Peer Reviewed verified by ORBi |
Absil, L., Journe, F., laurent, G., Frau, A., Ghanem, G., & Nonclercq, D. (30 January 2016). Phenotypic variations associated to V600EBRAF mutation among metastatic melanoma cell lines [Poster presentation]. BACR Annual Meeting, ULB Erasme, Belgium. |
Descamps, G., Karaca, Y., Lechien, J., Kindt, N., Decaestecker, C., Remmelink, M., Andry, G., Rodriguez, A., Khalife, M., Journe, F., & Saussez, S. (30 January 2016). The classical risk factors predict recurrence and survival after concomitant chemoradiotherapy in advanced head and neck cancer patients unlike the HPV status [Poster presentation]. BACR Annual Meeting, ULB Erasme, Belgium. |
Wattier, A., Arcolia, V., Doumont, G., Boutry, S., Journe, F., & Saussez, S. (04 December 2015). Development of an orthotopic mouse model of human Anaplastic Thyroid Carcinoma [Poster presentation]. Televie's researchers seminar: towards new therapies for cancer patients, Gembloux , Belgium. |
El Hajj, P., Gilot, D., Migault, M., Theunis, A., van Kempen, L., Sales, F., Fayyad-Kazan, H., Badran, B., Larsimont, D., Awada, A., Bachelot, L., Galibert, M., Ghanem, G., & Journe, F. (30 June 2015). SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma. British Journal of Cancer, 113, 91-98. Peer Reviewed verified by ORBi |
Verfaille, A., Imrichova, H., Atak, Z., Dewaele, M., Rambow, F., Hulselmans, G., Christiaens, V., Svetlichnyy, D., Luciani, F., van den Mooter, L., Claerhout, S., Fiers, M., Journe, F., Ghanem, G., Hermann, C., Halder, G., Marine, J., & Aerts, S. (09 April 2015). Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nature Communications, 6, 6683-6692. Peer Reviewed verified by ORBi |
Journe, F., Wiedig, M., Monrandini, R., El Hajj, P., Krayem, M., Sales, F., Theunis, A., Larsimont, D., Absil, L., Laurent, G., Gilot, D., Galibert, M.-D., Awada, A., & Ghanem, G. (08 March 2013). Tyrosine-related protein 1 (TYRP1) expression correlates with markers of both differentiation/pigmentation and proliferation in melanoma [Poster presentation]. Journée des doctorants, Bruxelles, Belgium. |
